Participants (n = 35) | Dropouts (n = 14) | p-value | |
---|---|---|---|
Age at diagnosis | 39 ± 13 | 36 ± 13 | 0.53 |
Sex (males) | 33 (94%) | 14 (100%) | 1.0 |
FVC% predicted | 102 ± 17 | 97 ± 13 | 0.37 |
FEV1% predicted | 91 ± 16 | 90 ± 16 | 0.89 |
FEV1/FVC | 75 ± 9 | 74 ± 10 | 0.50 |
PD20 (mg) | 0.95 (1.7) | 0.30 (0.5) | 0.03 |
NSBHR positivity | 23 (68%) | 11 (92%) | 0.13 |
Total exposure time (months) | 51 (104) | 74 (89) | 0.77 |
Time with symptoms (months) | 12 (26) | 24 (31) | 0.38 |
Smokers | 10 (29%) | 6 (43%) | 0.5 |
Pack-years* | 25 (24) | 13 (14) | 0.16 |
Upper airway symptoms | 28 (80%) | 11 (79) | 1.0 |
Asthma symptoms | 34 (97%) | 14 (100) | 1.0 |
Asthma medication | 31 (91%) | 8 (89) | 1.0 |